Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.46 |
| ▸ | LPL | P06858 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL27468236 | 0.83 | TP53 (0.59) | TP53TAAR1CYP2A6LPLLIPG | |
| SCHEMBL1803971 | 0.83 | ESR1 (0.32) | ALDH1A1TSHRTDP1 | |
| SCHEMBL36295 | 0.83 | TP53 (0.67) | TP53TAAR1CYP2A6LPLLIPG | |
| SCHEMBL51393 | 0.81 | — | — | |
| Formaldehyde SCHEMBL27479517 | 0.80 | TP53 (0.56) | TP53TAAR1CYP2A6LPLLIPG | |
| SCHEMBL31498555 | 0.79 | TP53 (0.62) | TP53TAAR1CYP2A6LPLLIPG | |
| Hydrogen Sulfide SCHEMBL29290777 | 0.79 | TP53 (0.62) | TP53TAAR1CYP2A6LPLLIPG | |
| SCHEMBL7542835 | 0.79 | TP53 (0.62) | TP53TAAR1CYP2A6LPLLIPG | |
| Ammonia Solution, Strong SCHEMBL27293386 | 0.79 | TP53 (0.62) | TP53TAAR1CYP2A6LPLLIPG | |
| Hydrogen Sulfide SCHEMBL27925242 | 0.79 | TP53 (0.62) | TP53TAAR1CYP2A6LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 784 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117799197-A | Large-area electrochromic device and preparation method thereof | 绍兴百立盛新材料科技有限公司 | 2024-04-02 | — | — | CN | claimed |
| US-11897789-B2 | Polymer/carbon nanotube composite and methods for wastewater treatment | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2024-02-13 | — | — | US | claimed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | claimed |
| EP-3802489-A2 | MASP-2 INHIBITORS AND METHODS OF USE | Omeros Corporation (US) | 2021-04-14 | — | — | EP | claimed |
| WO-2017199103-A1 | BENZAMIDE COMPOUNDS AS ROR GAMMA MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2017-11-23 | — | — | WO | claimed |
| EP-3087060-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2016-11-02 | — | — | EP | claimed |
| EP-1294699-B1 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORP (US) | 2016-04-13 | — | — | EP | claimed |
| WO-2015096651-A1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-02 | — | — | WO | claimed |
| CN-102015651-B | Compounds and compositions as TLR activity modulators | IRM LLC | 2014-12-31 | — | — | CN | claimed |
| US-8518999-B2 | Modulators of TNF-αsignaling | GENZYME CORPORATION (US) | 2013-08-27 | — | — | US | claimed |
| US-20030195187-A1 | Guanidino compounds | CHIRON CORPORATION | 2003-10-16 | — | — | US | claimed |
| CN-1441787-A | Modulators of TNF-alpha signaling | GENZYME CORP (US) | 2003-09-10 | — | — | CN | claimed |
| WO-2003066597-A2 | GUANIDINO COMPOUNDS | CHIRON CORPORATION (US) | 2003-08-14 | — | — | WO | claimed |
| EP-1294699-A2 | MODULATORS OF TNF- ALPHA SIGNALLING | GENZYME CORPORATION (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020119988-A1 | Antiinflammatory agents | GENZYME CORPORATION | 2002-08-29 | — | — | US | claimed |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-30 | — | — | US | claimed |
| WO-2001087849-A2 | MODULATORS OF TNF- ALPHA SIGNALING | GENZYME CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| US-4500538-A | Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure | MERCK & CO., INC. (US) | 1985-02-19 | — | — | US | claimed |
| EP-0122178-A2 | Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-10-17 | — | — | EP | claimed |
| US-4470991-A | Benzothiazolesulfonamide derivatives for the topical treatment of elevated intraocular pressure | MERCK & CO., INC. (US) | 1984-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195187-A1 | Guanidino compounds | MC4R, MC2R, GPR4 | TP53 4044/4885TAAR1 665/4885CYP2A6 3160/4885 |
| US-20020065248-A1 | Inhibitors of hepatitis C virus NS3 protease | TMPRSS15, CTRC, CPN1 | TP53 1043/4885TAAR1 2386/4885CYP2A6 595/4885 |
| US-20020119988-A1 | Antiinflammatory agents | TNF, TNFRSF1A, CD40 | TP53 4343/4885TAAR1 893/4885CYP2A6 1063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.